You need JavaScript to view this

Development of a therapeutic radiopharmaceutical {sup 177}Lu-DOTA- Minigastrin for potential use in PRRT; Desarrollo de un radiofarmaco terapeutico {sup 177}Lu-DOTA-Minigastrina para su potencial uso en PRRT

Abstract

The aim of this work is to obtain {sup 177}Lu-DOTA-Minigastrin with high radiochemical purity (RP) and the highest specific activity (Ae) as possible, using a locally produced (Nuclear Reactor RA-3, Ezeiza Atomic Center) {sup 177}LuCl{sub 3} of an intermediate level of Ae (between 6.36 to 17.95 Ci/mg of {sup 176}Lu) ) and also to perform in vitro and in vivo stability tests, dose calculation in normal mice and its extrapolation to a human model. (authors) [Spanish] El objetivo de este trabajo consistio en obtener {sup 177}Lu-DOTA-Minigastrina con una alta pureza radioquimica (PR) y la mayor actividad especifica (Ae) posible, empleando {sup 177}LuCl{sub 3} de media Ae (entre 6,36-17,95 Ci/mg de {sup 176}Lu) de produccion local (Reactor Nuclear RA-3, Centro Atomico Ezeiza), y realizar los ensayos de estabilidad in vitro e in vivo, el calculo de dosis en ratones normales y su extrapolacion a un modelo humano. (autores)
Authors:
Lopez Bularte, A. C.; Nevares, N. N.; Zapata, A. M.; Perez, J. H.; Crudo, J. L.; [1]  Puerta Yepes, N.; Rojo, A. M. [2] 
  1. Comision Nacional de Energia Atomica (Argentina)
  2. Autoridad Regulatoria Nuclear (Argentina)
Publication Date:
Jul 01, 2010
Product Type:
Conference
Report Number:
INIS-AR-A-14
Resource Relation:
Conference: Annual Price 'Florencio Fiorini' from the Florencio Fiorini Foundation and the University of Salvador, Buenos Aires (Argentina), 2010; Other Information: 13 refs., 13 figs., 5 tabs.; Related Information: In: Technical Memory 2010. Nuclear Regulatory Authority| 228 p.
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 61 RADIATION PROTECTION AND DOSIMETRY; EXTRAPOLATION; IN VITRO; IN VIVO; LUTETIUM 177; MICE; NUCLEAR MEDICINE; RADIATION DOSES; RADIOPHARMACEUTICALS
OSTI ID:
22142153
Research Organizations:
Autoridad Regulatoria Nuclear, Buenos Aires (Argentina)
Country of Origin:
Argentina
Language:
Spanish
Other Identifying Numbers:
TRN: AR13A0081096787
Availability:
Available from INIS in electronic form. Also available on-line at http://www.arn.gob.ar/images/stories/informes_y_documentos/memoria_tecnica/MT_2010/mt15_10_puerta_yepes.pdf
Submitting Site:
INIS
Size:
page(s) 123-140
Announcement Date:
Oct 24, 2013

Citation Formats

Lopez Bularte, A. C., Nevares, N. N., Zapata, A. M., Perez, J. H., Crudo, J. L., Puerta Yepes, N., and Rojo, A. M. Development of a therapeutic radiopharmaceutical {sup 177}Lu-DOTA- Minigastrin for potential use in PRRT; Desarrollo de un radiofarmaco terapeutico {sup 177}Lu-DOTA-Minigastrina para su potencial uso en PRRT. Argentina: N. p., 2010. Web.
Lopez Bularte, A. C., Nevares, N. N., Zapata, A. M., Perez, J. H., Crudo, J. L., Puerta Yepes, N., & Rojo, A. M. Development of a therapeutic radiopharmaceutical {sup 177}Lu-DOTA- Minigastrin for potential use in PRRT; Desarrollo de un radiofarmaco terapeutico {sup 177}Lu-DOTA-Minigastrina para su potencial uso en PRRT. Argentina.
Lopez Bularte, A. C., Nevares, N. N., Zapata, A. M., Perez, J. H., Crudo, J. L., Puerta Yepes, N., and Rojo, A. M. 2010. "Development of a therapeutic radiopharmaceutical {sup 177}Lu-DOTA- Minigastrin for potential use in PRRT; Desarrollo de un radiofarmaco terapeutico {sup 177}Lu-DOTA-Minigastrina para su potencial uso en PRRT." Argentina.
@misc{etde_22142153,
title = {Development of a therapeutic radiopharmaceutical {sup 177}Lu-DOTA- Minigastrin for potential use in PRRT; Desarrollo de un radiofarmaco terapeutico {sup 177}Lu-DOTA-Minigastrina para su potencial uso en PRRT}
author = {Lopez Bularte, A. C., Nevares, N. N., Zapata, A. M., Perez, J. H., Crudo, J. L., Puerta Yepes, N., and Rojo, A. M.}
abstractNote = {The aim of this work is to obtain {sup 177}Lu-DOTA-Minigastrin with high radiochemical purity (RP) and the highest specific activity (Ae) as possible, using a locally produced (Nuclear Reactor RA-3, Ezeiza Atomic Center) {sup 177}LuCl{sub 3} of an intermediate level of Ae (between 6.36 to 17.95 Ci/mg of {sup 176}Lu) ) and also to perform in vitro and in vivo stability tests, dose calculation in normal mice and its extrapolation to a human model. (authors) [Spanish] El objetivo de este trabajo consistio en obtener {sup 177}Lu-DOTA-Minigastrina con una alta pureza radioquimica (PR) y la mayor actividad especifica (Ae) posible, empleando {sup 177}LuCl{sub 3} de media Ae (entre 6,36-17,95 Ci/mg de {sup 176}Lu) de produccion local (Reactor Nuclear RA-3, Centro Atomico Ezeiza), y realizar los ensayos de estabilidad in vitro e in vivo, el calculo de dosis en ratones normales y su extrapolacion a un modelo humano. (autores)}
place = {Argentina}
year = {2010}
month = {Jul}
}